Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Tocilizumab
Synonyms
Therapy Description

Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tocilizumab Actemra Atlizumab Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05233397 Phase II Tocilizumab ACTEMRA for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Recruiting USA | CAN | AUS 0
NCT04007029 Phase I Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT05533775 Phase Ib/II Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) Recruiting USA | ITA | FRA | ESP | DNK | DEU | AUS 1
NCT03467373 Phase I Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Glofitamab-gxbm Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas Active, not recruiting USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS 0
NCT04246086 Phase Ib/II Tocilizumab Lenalidomide + Mosunetuzumab-axgb A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma Recruiting USA | GBR | FRA | ESP 1
NCT06016179 Phase I Tocilizumab Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Recruiting USA 0
NCT03671018 Phase I Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine + Obinutuzumab Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb Obinutuzumab Tocilizumab A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Active, not recruiting USA | GBR | ESP | CAN | BEL 0
NCT02906371 Phase I Tocilizumab Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome Completed USA 0
NCT03677141 Phase Ib/II Tocilizumab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Completed USA | POL | FRA | ESP | AUT 1
NCT06043674 Phase II Tocilizumab Atezolizumab + Glofitamab-gxbm + Obinutuzumab Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq Glofitamab-gxbm + Obinutuzumab A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation Recruiting USA 0
NCT02057770 Phase I Busulfan + Cyclophosphamide + Fludarabine Tocilizumab Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT05927571 Phase I Cevostamab + Elranatamab-bcmm Tocilizumab A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) Recruiting ISR | AUS 1
NCT04547062 Phase I Tocilizumab Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) (Tocilam) Completed FRA 0
NCT03970226 Phase I Tocilizumab Tocilizumab in Children With ACP Recruiting USA 0


Additional content available in CKB BOOST